^
Association details:
| Biomarker: | BCL2A1 overexpression |
|---|---|
| Cancer: | Chronic Lymphocytic Leukemia |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Identification of Recurrent Genomic Alterations in the Apoptotic Machinery in CLL Patients Treated with Venetoclax Monotherapy
Published date:
11/06/2019
Excerpt:
Comparison of mRNA expression pre- and post-VEN treatment demonstrated increased expression at the time of progression of key apoptotic genes BCL2L1 (BCL-XL), MCL1 and BCL2A1, all of which are known resistance factors to VEN.
DOI:
https://doi.org/10.1182/blood-2019-127458
